Phase 2 Ziv-aflibercept in Ocular Disease Short and Long-term Study

Next Previous
Trial Profile

Phase 2 Ziv-aflibercept in Ocular Disease Short and Long-term Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Retinal disorders
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Oct 2017 Results (n=60) assessing long-term safety and efficacy of ziv-aflibercept in retinal diseases, were published in the British Journal of Ophthalmology.
    • 03 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top